Archive for the ‘china retractions’ Category
We’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.
Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.
Sometimes publishers and authors decide it’s easier to retract a paper than leave it up for discussion by other scientists.
That seems to be the case here: The authors of a paper in Langmuir retracted it in September for a math mistake, but not before the journal refused to publish a comment criticizing the publication.
Although it shocks some observers every time, we’ve reported on the retractions of more than 100 papers pulled because authors managed to do their own peer review.
Apparently, it’s happened again.
Here’s a retraction notice in BMC Systems Biology for “Predicting new molecular targets for rhein using network pharmacology,” by Aihua Zhang, Hui Sun, Bo Yang and Xijun Wang:
Acta Radiologica has pulled a 2012 article on breast cancer imaging for being a duplicate publication — a sin the retraction notice takes great pains to point out.
As we’ve pointed out before, economics and business journals have few retractions compared with the other academic literature. Opinions vary on why this is, but the fact that only a few journals have plagiarism policies can’t help.
Research Papers in Economics, or RePEc, an organization that maintains a database of economics papers, however, thoroughly investigates accusations of misconduct. A RePEc report, which indicated that the plagiarists were polite enough to cite the original paper, was used in the notice as evidence for a retraction in Economic Modelling.
A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.
Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »